Hip fracture

British Medical Journal

Volumn 333, Issue 7557, 2006, Pages 27-30

  Parker, Martyn ^a   Johansen, Antony ^b  

^a PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; UNCLASSIFIED DRUG; VITAMIN D;

ANALGESIA; ARTHROPLASTY; BLEEDING; BONE RADIOGRAPHY; BONE SCREW; CLINICAL TRIAL; CONSERVATIVE TREATMENT; EMERGENCY HEALTH SERVICE; FRACTURE FIXATION; FRACTURE REDUCTION; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; IMMOBILIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; ORTHOPEDIC SURGERY; OSTEOSYNTHESIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REHABILITATION; REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TRACTION THERAPY; TREATMENT OUTCOME; FORECASTING; PEROPERATIVE CARE;

FORECASTING; HIP FRACTURES; HUMANS; INTRAOPERATIVE CARE;

EID: 33745901921     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.333.7557.27     Document Type: Review

References (21)

1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporosis Int 1997;7:407-13.
2. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fracture. BMJ 1993;307:1248-50.
3. Roche JJW, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 2006;31:1374-6.
4. Parker MJ, Handoll HHG. Hip fracture. Clinical evidence. BMJ Publishing, 2005.
5. Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of hip fractures in older people. SIGN Publication No 56. Edinburgh: SIGN. 2002. www.sign.ac.uk/guidelines/fulltext/56/index.html (last accessed 6 Jun 2006).
6. New Zealand Guidelines Group. Acute management and immediate rehabilitation after hip fracture amongst people aged 65 years and over. 2003. www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineCatID = 32&guidelineID = 7 (last accessed 6 Jun 2006).
7. March LM, Chamberlain AC, Cameron ID, Cumming RG, Brnabic AJM, Finnegan TP, et al. How best to fix the broken hip. Med J Aust 1999;170:489-94.
8. Cameron I, Crotty M, Curry C, Finnegan T, Gillespie L, Gillespie W, et al. Geriatric rehabilitation following fractures in older people: a systematic review. Health Technol Assess 2000;4(2):i-iv, 1-111.
9. Department of Health. National service framework for older people. London: DoH, 2001 www.dh.gw.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ID = 4003066&chk = wg3bg0 (last accessed 8 Jun 2006).
10. Cameron ED, Handoll HHG, Finnegan TP, Madhok R, Langhorne P. Co-ordinated multidisciplinary approaches for inpatient rehabilitation of older patients with proximal femoral fractures. Cochrane Database Syst Rev 2001;(3):CD000106.
11. Gillespie LD, Gillespie WJ, Cumming R, Lamb SE, Rowe BH. Interventions for preventing falls in the elderly. Cochrane Database Syst Rev 2003;(4):CD000340.
12. American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons. National guidelines for the prevention of falls in older persons. 2001. http://www.americangeriatrics.org/products/positionpapers/ Falls.pdf (last accessed 6 Jun 2006).
13. National Institute for Health and Clinical Assessment. Clinical practice guideline for the assessment and prevention of falls in older people. London: NICE, 2004. www.nice.org.uk/page.aspx?o = cg021fullguideline (last accessed 6 Jun 2006).
14. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for 3 years on hip fractures in elderly women. BMJ 1994;308:1081-2.
15. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005;(3):CD000227.
16. National Institute for Health and Clinical Excellence, Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2005. www.nice.org.uk/pdf/TA087guidance.pdf (last accessed 6 Jun 2006).
17. Boonen S, McClung MR, Eastell R, Fuleihan GE-H, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1836-9.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results for the Women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
19. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999;281:2189-97.
20. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2005;(3):CD001255.
21. Parker MJ, Gillespie L, Gillespie W. Hip protectors for preventing hip fractures in the elderly: the evolution of a systematic review of randomised controlled trials. BMJ 2006;332:571-3.